CRISPR Therapeutics Stock - Weekly review against gene-editing peers

CRISPR Therapeutics stock ends the week near the mid-50 dollar range on Nasdaq, after a relatively calm few sessions in gene editing. A closer look shows how CRSP has performed versus key genome-editing and biotech peers over the past week.

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:28 CET. Details in the imprint.

CRISPR Therapeutics (CH0334081137) closes this week with its Nasdaq-listed stock trading in the mid-50 dollar range after a largely orderly few sessions in gene-editing names. With no fresh company disclosures on Friday, the focus shifts to how CRSP has tracked the broader biotech and gene-editing space over the past week.

How CRSP traded this week

Over the past several sessions, CRISPR Therapeutics shares have hovered roughly in the mid-50 dollar area on Nasdaq, with modest day-to-day fluctuations rather than sharp swings. Intraday ranges were comparatively tight, pointing to a more measured trading pattern after earlier volatility in gene-editing stocks.

Trading activity has centered around levels close to the prior week’s close, suggesting a phase of consolidation where new fundamental impulses from company-specific news or macro drivers were limited. For many investors, this kind of sideways movement serves as a period to reassess positioning after stronger moves earlier in the year.

Weekly comparison with gene-editing peers

Against this backdrop, a weekly review highlights how CRSP has performed relative to other gene-editing and broader biotech names. While price paths differ in detail, the general pattern across several genome-editing companies this week has been one of restrained moves, with no broad-based sector rally or selloff dominating trading.

Compared with larger diversified biotech and pharmaceutical groups, CRISPR Therapeutics remains exposed to higher sentiment swings due to its more focused pipeline and earlier-stage programs. Over this particular week, however, the gap in volatility versus some larger healthcare constituents appears more muted than in previous periods.

The business behind the stock

CRISPR Therapeutics generates its value proposition from developing gene-editing therapies based on CRISPR/Cas9 technology across areas such as hemoglobinopathies, oncology and other serious diseases. In partnership settings and wholly owned programs, the company aims to translate this platform into approved, commercially viable treatments.

Where the stock trades today

CRISPR Therapeutics shares trade on Nasdaq in the United States under the ticker CRSP, recently quoted in the mid-50 dollar range during trading on 06/19/2026, based on the latest available indicative data.

Key facts on CRISPR Therapeutics stock

• Company: CRISPR Therapeutics AG
• ISIN: CH0334081137
• WKN: A2AT0Z
• Ticker: CRSP
• Venue: Nasdaq
• Price (as of 06/19/2026, 20:28 CET): mid-50s USD range (indicative)
• Market cap: around mid-single-digit billion USD range (as of 06/19/2026)
• Sector / Industry: Health Care / Biotechnology
• Index membership: not a member of the S&P 500 or Nasdaq-100, listed on Nasdaq biotechnology universe
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.